[Systemic therapy strategies for head-neck carcinomas: current status].

Area of Science:

• Oncology
• Cancer Therapeutics
• Head and Neck Oncology

Background:

• Head and neck cancers, predominantly squamous cell tumors, have a poor prognosis due to recurrences and metastases.
• Standard surgical and radiation treatments are often insufficient, necessitating effective systemic therapies.

Purpose of the Study:

• To review current and emerging systemic treatment strategies for head and neck cancers.
• To evaluate the efficacy, toxicity, and impact on quality-of-life of various systemic therapies.

Main Methods:

• Review of antineoplastic chemotherapy, including induction and palliative regimens.
• Evaluation of targeted therapies, such as EGFR-specific antibodies.
• Discussion of novel biologicals like signal cascade inhibitors, genetic agents, and immunotherapies.

Main Results:

• Triple-combination induction therapy shows high remission rates but significant toxicity.
• EGFR-specific antibodies are effective in palliative and advanced settings.
• Novel biologicals are under investigation for advanced, recurrent, or metastatic disease.

Conclusions:

• Systemic therapies are crucial for managing advanced, recurrent, or metastatic head and neck cancers.
• Future treatment development must consider efficacy, toxicity, quality-of-life, and predictive biomarkers.
• Targeted therapies and immunotherapies represent promising avenues for personalized treatment.